Asset profile
AV-101
Small molecule
Evidence outlook · lead readout
NCT03078322 · Major Depressive Disorder
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03078322: The study was randomized and quadruple-blind, compared AV-101 with placebo, and enrolled 180 participants; its primary endpoint was the clinical MADRS-10 depression score. Because the registry does not report whether the primary endpoint was met, the trial provides promising design information but no confirmed evidence of benefit.
Also in development:Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.